Incidence and survival of peritoneal malignant mesothelioma between 1989 and 2015: A population-based study

Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin. Abdel-Rahman, 2018, Global trends in mortality from malignant mesothelioma: analysis of WHO mortality database (1994-2013), Clin. Respir. J., 12, 2090, 10.1111/crj.12778 Marinaccio, 2018, The epidemiology of malignant mesothelioma in women: gender differences and modalities of asbestos exposure, Occup. Environ. Med., 75, 254, 10.1136/oemed-2016-104119 Galateau-Sallé, 2006 Boffetta, 2007, Epidemiology of peritoneal mesothelioma: a review, Ann. Oncol., 18, 985, 10.1093/annonc/mdl345 Gatta, 2011, Rare cancers are not so rare: the rare cancer burden in Europe, Eur. J. Cancer, 47, 2493, 10.1016/j.ejca.2011.08.008 Judge, 2016, Malignant peritoneal mesothelioma: characterization of the inflammatory response in the tumor microenvironment, Ann. Surg. Oncol., 23, 1496, 10.1245/s10434-015-4965-6 Yan, 2009, Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multiinstitutional experience, J. Clin. Oncol., 27, 6237, 10.1200/JCO.2009.23.9640 Cowppli-Bony, 2017, Survival of solid cancer patients in France, 1989-2013: a population-based study, Eur. J. Cancer Prev., 26, 461, 10.1097/CEJ.0000000000000372 Le Stang, 2010, Evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and 2005, Int. J. Cancer, 126, 232, 10.1002/ijc.24711 Galateau-Sallé, 2014, The French mesothelioma network from 1998 to 2013, Ann. Pathol., 34, 51, 10.1016/j.annpat.2014.01.009 Segi, 1954, A proposal on a calculation method to be applied by geographical comparison of cancer mortality, Tohoku J. Exp. Med., 60, 307, 10.1620/tjem.60.307 Gilg Soit Ilg, 2015, Programme national de surveillance du mésothéliome (PNSM). Actualisation des principaux résultats, Bull. Epidémiol. Hebd., 28 Salo, 2017, Epidemiology of malignant peritoneal mesothelioma: a population-based study, Cancer Epidemiol., 51, 81, 10.1016/j.canep.2017.10.008 Mensi, 2017, Differences between peritoneal and pleural mesothelioma in Lombardy, Italy, Cancer Epidemiol., 51, 68, 10.1016/j.canep.2017.10.003 Siesling, 2012, Rare thoracic cancers, including peritoneum mesothelioma, Eur. J. Cancer, 48, 949, 10.1016/j.ejca.2012.02.047 Mirabelli, 2009, Survival of peritoneal malignant mesothelioma in Italy: a population-based study, Int. J. Cancer, 124, 194, 10.1002/ijc.23866 Montanaro, 2009, Survival of pleural malignant mesothelioma in Italy: a population-based study, Int. J. Cancer, 124, 201, 10.1002/ijc.23874 Soeberg, 2016, Incidence and survival trends for malignant pleural and peritoneal mesothelioma, Australia, 1982-2009, Occup. Environ. Med., 73, 187, 10.1136/oemed-2015-103309 Cao, 2012, Importance of gender in diffuse malignant peritoneal mesothelioma, Ann. Oncol., 23, 1494, 10.1093/annonc/mdr477 Bueno, 2016, Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations, Nat. Genet., 48, 407, 10.1038/ng.3520 Guo, 2015, Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma, Cancer Res., 75, 264, 10.1158/0008-5472.CAN-14-1008 De Rienzo, 2016, Gender-specific molecular and clinical features underlie malignant pleural mesothelioma, Cancer Res., 76, 319, 10.1158/0008-5472.CAN-15-0751 Singhi, 2016, The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma, Mod. Pathol., 29, 14, 10.1038/modpathol.2015.121 Leblay, 2017, BAP1 is altered by copy number loss, mutation, and/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas, J. Thorac. Oncol., 12, 724, 10.1016/j.jtho.2016.12.019 Baumann, 2015, Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival, Carcinogenesis, 36, 76, 10.1093/carcin/bgu227 Malgras, 2018, Impact of combination chemotherapy in peritoneal mesothelioma hyperthermic intraperitoneal chemotherapy (HIPEC): the RENAPE study, Ann. Surg. Oncol., 25, 3271, 10.1245/s10434-018-6631-2 Villeneuve, 2017, The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry, Orphan. J. Rare Dis., 12, 37, 10.1186/s13023-017-0571-y Villeneuve, 2014, The RENAPE network: towards a new healthcare organization for the treatment of rare tumors of the peritoneum. Description of the network and role of the pathologists, Ann. Pathol., 34, 4, 10.1016/j.annpat.2014.01.008 Kepenekian, 2016, Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: multi-Institutional Retrospective Study, Eur. J. Cancer, 65, 69, 10.1016/j.ejca.2016.06.002